Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.

被引：0
|
作者：
Lu, Nian
Jiang, Yao-Fei
Xia, Weixiong
Huang, Ying
Xie, Chuan-Miao
Xu, Cheng
Ye, Yan-Fang
Liu, Guo-Ying
Bei, Wei-Xin
Ke, Liang-Ru
Li, Wang-Zhong
Wang, Xin
Xie, Changqing
Liang, Hu
Xiang Yanqun
机构：
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc,Guangdong Key Lab Nasopharyngeal Carcino, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Dept Radiat Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Clin Res Design Div, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[8] Sun Yat Sen Univ, Dept Nasopharyngeal Carcinoma, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[9] Sun Yat Sen Univ, Dept Med Imaging, Ctr Canc, Guangzhou, Peoples R China
[10] Guangzhou Med Univ, Affiliated Hosp 1, Dept Thorac Surg & Oncol,Guangzhou Inst Resp Hlth, Natl Clin Res Ctr Resp Dis,State Key Lab Resp Dis, Guangzhou, Peoples R China
[11] NCI, Thorac & GI Malignancies Branch, Ctr Canc Res, NIH, Bethesda, OH USA
[12] NCI, Thorac & GI Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6031
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study
    Lu, Nian
    Jiang, Yao-Fei
    Xia, Wei-Xiong
    Huang, Ying
    Xie, Chuan-Miao
    Xu, Cheng
    Ye, Yan-Fang
    Liu, Guo-Ying
    Bei, Wei-Xin
    Ke, Liang-Ru
    Li, Wang-Zhong
    Zhang, Cheng
    Wang, Xin
    Liu, Qin
    Chen, Xi
    Chen, Zi-Xiong
    Xie, Changqing
    Liang, Hu
    Xiang, Yan-Qun
    ECLINICALMEDICINE, 2023, 62
  • [2] Phase II study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy
    Peng, PeiJian
    Ou, XueQing
    Liao, Hai
    Liu, YuMeng
    Wang, SiYang
    Cheng, ZhiBin
    Lin, Zhong
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (03) : 153 - 159
  • [3] Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy
    Zhang, Yang
    Zhao, Liping
    Huang, Peiyu
    Wu, Jingxun
    Wang, Fenghua
    Huang, Yan
    Zhang, Li
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 611 - 615
  • [4] Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy
    Yang Zhang
    Liping Zhao
    Peiyu Huang
    Jingxun Wu
    Fenghua Wang
    Yan Huang
    Li Zhang
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 611 - 615
  • [5] A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy
    Chua, DTT
    Sham, JST
    Au, GKH
    ORAL ONCOLOGY, 2003, 39 (04) : 361 - 366
  • [6] Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
    Zhu, Yunshu
    Yang, Sheng
    Zhou, Shengyu
    Yang, Jianliang
    Qin, Yan
    Gui, Lin
    Shi, Yuankai
    He, Xiaohui
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [7] Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy
    Zhang, Li
    Zhang, Yang
    Huang, Pei-Yu
    Xu, Fei
    Peng, Pei-Jian
    Guan, Zhong-Zhen
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (01) : 33 - 38
  • [8] A phase II trial of erlotinib after gemcitabine plus platinum-based chemotherapy in patients (pts) with recurrent and/or metastatic nasopharyngeal carcinoma (NPC)
    You, B.
    Le Tourneau, C.
    Chen, E. X.
    Chin, S. F.
    Wang, L.
    Jarvi, A.
    Bharadwaj, R. R.
    Kamel-Reid, S.
    Perez-Ordonez, B.
    Siu, L. L.
    EJC SUPPLEMENTS, 2009, 7 (02): : 478 - 479
  • [9] Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy
    Li Zhang
    Yang Zhang
    Pei-Yu Huang
    Fei Xu
    Pei-Jian Peng
    Zhong-Zhen Guan
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 33 - 38
  • [10] A Phase II Trial of Erlotinib as Maintenance Treatment After Gemcitabine Plus Platinum-based Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
    You, Benoit
    Le Tourneau, Christophe
    Chen, Eric X.
    Wang, Lisa
    Jarvi, Andrea
    Bharadwaj, Rikki R.
    Kamel-Reid, Suzanne
    Perez-Ordonez, Bayardo
    Mann, Vijay
    Siu, Lillian L.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (03): : 255 - 260
12345